GB0009591D0 - Medical combinations - Google Patents

Medical combinations

Info

Publication number
GB0009591D0
GB0009591D0 GBGB0009591.9A GB0009591A GB0009591D0 GB 0009591 D0 GB0009591 D0 GB 0009591D0 GB 0009591 A GB0009591 A GB 0009591A GB 0009591 D0 GB0009591 D0 GB 0009591D0
Authority
GB
United Kingdom
Prior art keywords
medical combinations
medical
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0009591.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0009591.9A priority Critical patent/GB0009591D0/en
Publication of GB0009591D0 publication Critical patent/GB0009591D0/en
Priority to PCT/GB2001/001649 priority patent/WO2001078745A1/en
Priority to AU46723/01A priority patent/AU4672301A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0009591.9A 2000-04-18 2000-04-18 Medical combinations Ceased GB0009591D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0009591.9A GB0009591D0 (en) 2000-04-18 2000-04-18 Medical combinations
PCT/GB2001/001649 WO2001078745A1 (en) 2000-04-18 2001-04-11 Medical combinations comprising formoterol and fluticasone proprionate
AU46723/01A AU4672301A (en) 2000-04-18 2001-04-11 Medical combinations comprising formoterol and fluticasone proprionate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0009591.9A GB0009591D0 (en) 2000-04-18 2000-04-18 Medical combinations

Publications (1)

Publication Number Publication Date
GB0009591D0 true GB0009591D0 (en) 2000-06-07

Family

ID=9890176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0009591.9A Ceased GB0009591D0 (en) 2000-04-18 2000-04-18 Medical combinations

Country Status (3)

Country Link
AU (1) AU4672301A (en)
GB (1) GB0009591D0 (en)
WO (1) WO2001078745A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
EP2067784A3 (en) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL158222A0 (en) 2001-04-30 2004-05-12 Glaxo Group Ltd Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US7084153B2 (en) 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
DE10216429A1 (en) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Synergistic medicaments for treating inflammatory or obstructive respiratory tract diseases, containing quaternized scopine ester anticholinergic agent and steroid, e.g. budesonide
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP2319583A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium
SE527191C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Inhaler device and combined doses of tiotropium and fluticasone
SE527069C2 (en) 2003-06-19 2005-12-13 Mederio Ag Method and apparatus for administering drug powder
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (en) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
US7892483B2 (en) 2004-03-12 2011-02-22 Cipla Limited Sterilization process
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000622A2 (en) * 2010-01-28 2011-08-22 Bi̇lgi̇ç Mahmut Pharmaceutical combinations containing tiotropium.
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
MX2013004137A (en) 2010-10-12 2013-07-29 Cipla Ltd Pharmaceutical composition.
MX2014011576A (en) 2012-04-11 2014-11-21 Cipla Ltd Pharmaceutical composition comprising arformoterol and fluticasone furoate.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2088877B (en) * 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
AU722859B2 (en) * 1996-11-11 2000-08-10 Sepracor, Inc. Process for the preparation of optically pure isomers of formoterol
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2001078745A1 (en) 2001-10-25
AU4672301A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
AU6282901A (en) Medical arrangement
GB0009591D0 (en) Medical combinations
GB0009606D0 (en) Therapeutic combinations
AU8420301A (en) Use
GB0011244D0 (en) Tissue regrafting
GB0025788D0 (en) Use
GB0030541D0 (en) Medical uses
GB0005070D0 (en) Use
GB0029634D0 (en) Use
GB2358857B (en) Coffins
GB0031321D0 (en) Treatment
GB0016690D0 (en) Eplthelial diagnostic aid
GB0026771D0 (en) Medical uses
GB0015251D0 (en) Medical unit
AU144071S (en) Tissue
AU143950S (en) Tissue
AU143726S (en) Tissue
AU143951S (en) Tissue
AU9481201A (en) Human nedd-1
HU0000152V0 (en) Hearse
GB0017076D0 (en) Medicament
GB0017092D0 (en) Medicament
GB0017727D0 (en) Catheter
GB0010886D0 (en) Catheter
TW501478U (en) Coffin

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)